| Biomarker ID | 903 |
| PMID | 22505341 |
| Year | 2012 |
| Biomarker | ERG |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in TMPRSS2-ERG positive fusion cases |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer |
| Type of Biomarker | Prognostic |
| Cohort | Prostate specimens and urine sediments from 179 previously untreated patients with pT2-pT3 stage PCa were analyzed. 92 were TMPRSS2–ERG- positive cases and 66 were TMPRSS2–ERG- negative cases |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | ERG and SPINK1 expression levels were not different in tumor versus nontumor prostate tissues |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ERG |